Dosimetry in nuclear medicine therapy: What are the specifics in image quantification for dosimetry?

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 55, Issue 1, 2011, Pages 5-20

  Bardies M ^a   Buvat, I ^b  

^a UNIVERSITÉ DE NANTES   (France)

^b Centre National de la Recherche Scientifique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; DOSIMETRY; IMAGE ANALYSIS; IMAGE RECONSTRUCTION; POSITRON EMISSION TOMOGRAPHY; QUALITY CONTROL; QUANTITATIVE ANALYSIS; RADIATION ABSORPTION; RADIOACTIVITY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THREE DIMENSIONAL IMAGING;

3-IODOBENZYLGUANIDINE; BONE MARROW; CARCINOMA, HEPATOCELLULAR; HUMANS; IODINE RADIOISOTOPES; LIVER NEOPLASMS; LYMPHOMA, NON-HODGKIN; NEOPLASMS; NEUROENDOCRINE TUMORS; NUCLEAR MEDICINE; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; RADIOTHERAPY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79957529242     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Loevinger R, Budinger TF, Watson EE. MIRD primer for absorbed dose calculations, Revised. New York: The Society of Nuclear Medicine; 1991.
2. Lassmann M, Chiesa C, Flux, G and Bardiès M. EANM Dosimetry Committee Guidance Document: Good Practice of Clinical Dosimetry Reporting. Eur J Nucl Med Mol Imaging 2011;38:192-200.
3. Stabin MG, Bardiès M. Radiation dose assesment in nuclear medicine. In: Xu G, Eckerman KF, editors. Handbook of anatomical models for radiation dosimetry. Taylor and Francis Group, LCC; 2010.
4. Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF et al. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999;40:37S-61S.
5. Zaidi H, Hasegawa B. Determination of the attenuation map in emission tomography. J Nucl Med 2003;44:291-315.
6. Buvat I, Benali H, Todd-Pokropek A, Di Paola R. Scatter correction in scintigraphy: the state of the art. Eur J Nucl Med 1994;21:675-94. (Pubitemid 24211122)
7. Zaidi H, Koral KF. Scatter modelling and compensation in emission tomography. Eur J Nucl Med Mol Imaging 2004;31:761-82. (Pubitemid 38647918)
8. Laurette I, Zeng GL, Welch A, Christian PE, Gullberg GT. A three-dimensional ray-driven attenuation, scatter and geometric response correction technique for SPECT in inhomogeneous media. Phys Med Biol 2000;45:3459-80.
9. Parker JG, Mair BA, Gilland DR. Respiratory motion correction in gated cardiac SPECT using quaternion-based, rigid-body registration. Med Phys 2009;36:4742-54.
10. Soret M, Koulibaly PM, Darcourt J, Buvat I. Partial volume effect correction in SPECT for striatal uptake measurements in patients with neurodegenerative diseases: impact upon patient classification. Eur J Nucl Med Mol Imaging 2006;33:1062-72. (Pubitemid 44215672)
11. Verel I, Visser GW, and van Dongen GA. The promise of immuno-PET in radioimmunotherapy. J Nucl Med 2005;46:1164S-71S.
12. Walrand S, Jamar F, Mathieu I, De Camps J, Lonneux M, Sibomana M et al. Quantitation in PET using isotopes emitting prompt single gammas: application to yttrium-86. Eur J Nucl Med Mol Imaging 2003;30:354-61. (Pubitemid 36692859)
13. Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L et al. Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 2005;46:99S-106S.
14. Sgouros G, Kolbert KS, Sheikh A, Pentlow KS, Mun EF, Barth A et al. Patient-specific dosimetry for 131I thyroid cancer therapy using 1241 PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 2004;45:1366-72. (Pubitemid 47618537)
15. Jentzen W, Hobbs RF, Stahl A, Knust J, Sgouros G, and Bockisch A. Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2010;37:884-95.
16. Seo Y, Mari C, Hasegawa BH. Technological development and advances in single-photon emission computed tomography/computed tomography. Semin Nucl Med 2008;38:177-98. (Pubitemid 351466914)
17. Willowson K, Bailey DL, Baldock C. Quantitative SPECT reconstruction using CT derived corrections. Phys Med Biol 2008;53:3099-112. (Pubitemid 351892389)
18. Bacharach SL, Buvat I. Attenuation correction in cardiac PET and SPECT. J Nucl Cardiol 1995;2:246-55.
19. King MA, deVries DJ, Pan TS, Pretorius PH, Case JA. An investigation of the filtering of TEW scatter estimates used to compensate for scatter with ordered subset reconstructions. IEEE Trans Nucl Sci 1997;44:1140-5.
20. Dewaraja YK, Ljungberg M, Fessier JA. 3D Monte Carlo-based scatter compensation in quantitative I-131 SPECT reconstruction. IEEE Trans Nucl Sci 2006;53:181-8.
21. Soret M, Bacharach SL, Buvat I. Partial volume effect in PET tumor imaging. J Nucl. Med 2007;48:932-945. (Pubitemid 46909922)
22. Kovalski G, Keidar Z, Frenkel A, Sachs J, Attia S, Azhari H. Dual "motion-frozen heart" combining respiration and contraction compensation in clinical myocardial perfusion SPECT imaging. J Nucl Cardiol 2009;16:396-404.
23. Ljungberg M, Sjögreen K, Liu X, Frey E, Dewaraja Y, Strand SE. A 3-Dimensional absorbed dose calculation method based on quantitative SPECT for radionuclide therapy: evaluation for 131I using Monte Carlo simulation. J Nucl Med 2002;43:1101-9. (Pubitemid 34847935)
24. Dewaraja YK, Wilderman SJ, Ljungberg M, Koral KF, Zasadny K, Kaminiski MS. Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation. J Nucl Med 2005;46:840-9.
25. Chiesa C, Botta F, Coliva A, Maccauro M, Devizzi L, Guident A et al. Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin). Eur J Nucl Med Mol Imaging 2009;36:1745-57
26. 90Y- ibritumomab tiuxetan. J Nucl Med 2009;50:644-52.
27. Assié K, Dieudionné A, Gardin I, Buvat I, Tilly H, Véra P. Comparison between 2D and 3D dosimetry protocols in 90Y-Ibritumomab Tiuxetan Radioimmunotherapy of patients with non-Hodgkin's lymphoma. Cancer Biother Radiopharm 2008;23:53-64. (Pubitemid 351304220)
28. He B, Frey EC. Comparison of conventional, model-based quantitative planar, and quantitative SPECT image processing methods for organ activity estimation using In-111 agents. Phys Med Biol 2006;51:3967-81. (Pubitemid 44177401)
29. He B, Wahl RL, Sgouros G, Du Y, Jacene H, Kasecamp WR et al. Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning-patient studies. Med Phys 2009;36:1595-601.
30. Liu A, Williams LE, Raubitschek AA. A CT assisted method for absolute quantitation of internal radioactivity. Med Phys 1996;23:1919-28. (Pubitemid 26394094)
31. Song N, He B, Frey EC. The effect of volume-of-interest misregistration on quantitative planar activity and dose estimation. Phys Med Biol 2010;55:5483-97.
32. Ljungberg M, Frey E, Sjögreen K, Liu X, Dewaraja Y, Strand SE. 3D absorbed dose calculations based on SPECT: evaluation for 111-In/90-Y therapy using Monte Carlo simulations. Cancer Biother Radiopharm 2003;18:99-107. (Pubitemid 36307471)
33. Assié K, Dieudonné A, Gardin I, Véra P, Buvat I. A preliminary study of quantitative protocols in Indium 111 SPECT using computational simulations and phantoms. IEEE Trans Nucl Sci 2010;57:1096-104.
34. He B, Du Y, Segars WP, Wahl RL, Sgouros G, Jacene H et al. Evaluation of quantitative imaging methods for organ activity and residence time estimation using a population of phantoms having realistic variations in anatomy and uptake. Med Phys 2009;36:612-9.
35. He B, Frey EC. Effects of shortened acquisition time on accuracy and precision of quantitative estimates of organ activity. Med Phys 2010;37:1807-15.
36. He B, Frey EC. The impact of 3D volume of interest definition on accuracy and precision of activity estimation in quantitative SPECT and planar processing methods. Phys Med Biol 2010;55:3535-44.
37. Dewaraja YK, Wilderman SJ, Koral KF, Kaminski MS, Avram AM. Use of integrated SPECT/CT imaging for tumor dosimetry in I-131 radioimmunotherapy: a pilot patient study. Cancer Biother Radiopharm. 2009;24:417-26.
38. Necib H, Garcia C, Wagner A, Vanderlinden B, Emonts P, Hendlisz A et al. Detection and characterization of tumor changes in FDG PET patient monitoring using parametric imaging. J Nucl Med 2011;52 [In press].
39. Koral KF, Zasadny KR, Swailem FM, Buchbinder SF, Francis IR, Kaminski MS et al. Importance of intra-therapy single-photon emission tomographic imaging in calculating tumour dosimetry for a lymphoma patient. Eur J Nucl Med 1991;18:432-5.
40. de Wit TC, Xiao J, Nijsen JF, van het Schip FD, Staelens SG, van Rijk PP et al. Hybrid scatter correction applied to quantitative holmium-166 SPECT. Phys Med Biol 2006;51:4773-87.
41. Fabbri C, Sarti G, Cremonesi M, Ferrari M, Di Dia A, Agostini M et al. Quantitative analysis of 90Y Bremsstrahlung SPECT-CT images for application to 3D patient-specific dosimetry. Cancer Biother Radiopharm 2009;24:145-54.
42. Minarik D, Sjögreen Gleisner K, Ljungberg M. Evaluation of quantitative (90)Y SPECT based on experimental phantom studies. Phys Med Biol 2008;53:5689-703.
43. Minarik D, Ljungberg M, Segars P, Gleisner KS. Evaluation of quantitative planar 90Y bremsstrahlung whole-body imaging. Phys Med Biol 2009;54:5873-83.
44. Minarik D, Sjögreen-Gleisner K, Linden O, Wingårdh K, Tennvall J, Strand SE et al. 90Y Bremsstrahlung imaging for absorbed-dose assessment in high-dose radioimmunotherapy. J Nucl Med 2010;51:1974-8.
45. Hapdey S, Soret M, Ferrer L, Koulibaly PM, Henriques J, Bardiès M et al. Quantification in SPECT : myth or reality ? A multicentric study. IEEE Nuclear Science Symposium Conference Record 2004;5:3170-3. (Pubitemid 41147932)
46. Jan S, Santin G, Strul D, Staelens S, Assié K, Autret D et al. GATE: a simulation toolkit for PET and SPECT. Phys Med Biol 2004;49:4543-61. (Pubitemid 39378244)
47. McKay E, Ferrer L, Barbet J, Bardiès M. TestDose: Software for creating dosimetry problems. J Nucl Med 2009;50(Supp 2):392.
48. Ferrer L, McKay E, Lisbona A, Kraeber-Bodéré F, Bardiès M. DosiTest : Accuracy of radio-immunotherapy dosimetry protocol. J Nucl Med 2009;50(Supp 2):392p.
49. Stabin MG. Uncertainties in internal dose calculations for radiopharmaceuticals. J Nucl Med 2008;49:853-60. (Pubitemid 351717553)
50. Flux GD, Guy MJ, Beddows R, Pryor M, Flower MA. Estimation and implications of random errors in whole-body dosimetry for targeted radionuclide therapy. Phys Med Biol 2002;47:3211-23.
51. Brans B, Bodei L, Giammarile F, Linden O, Luster M, Oyen WJ et al. Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray". Eur J Nucl Med Mol Imaging 2007;34:772-86
52. Sgouros G. Toward patient-friendly cell-level dosimetry. J Nucl Med 2007;48:496.
53. Council directive 97/43 EURATOM 1997
54. Salvatori M, Luster M. Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2010;37:821-8.
55. Lassmann M, Hänscheid H, Chiesa C, Hindorf C, Flux G, Luster M et al. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging 2008;35:1405-12.
56. Verburg FA, Hänscheid H, Biko J, Hategan MC, Lassmann M, Kreissl MC et al. Dosimetry-guided high-activity (131) I therapy in patients with advanced differentiated thyroid carcinoma: initial experience. Eur J Nucl Med Mol Imaging 2010;37:896-903.
57. Flux GD, Haq M, Chittenden SJ, Buckley S, Hindorf C, Newbold K et al. A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2010;37:270-5.
58. Sisson JC, Dewaraja YK, Wizauer EJ, Giordano TJ, Avram AM. Thyroid carcinoma metastasis to skull with infringement of brain: treatment with radioiodine. Thyroid 2009;19:297-303.
59. Matthay KK, Panina C, Huberty J, Price D, Glidden DV, Tang HR et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. J Nucl Med. 2001;42:1713-21. (Pubitemid 33131334)
60. Buckley SE, Chittenden SJ, Saran FH, Meller ST, Flux GD. Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma. J Nucl Med 2009;50:1518-24.
61. Wahl RL, Kroll S, Zasadny KR. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. J Nucl Med 1998;39(suppl):14S-20S.
62. Dewaraja YK, Schipper MJ, Roberson PL, Wilderman SJ, Amro H, Regan DD et al. 1311-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling. J Nucl Med 2010;51:1155-62.
63. Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med 2003;44:465-74. (Pubitemid 39586026)
64. Cremonesi M, Ferrari M, Grana CM et al. High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment. J Nucl Med 2007;48:1871-9. (Pubitemid 350103424)
65. Ferrer L, Kraeber-Bodéré F, Bodet-Milin C, Rousseau C, Le Gouill S, Wegener WA et al. Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy. Cancer 2010;116(4 Suppl):1093-100.
66. Ferrer L, Malek E, Bodet-Millin C, LeGouill S, Prangère T, Robu D et al. Comparison of dosimetric approaches for non hodgkin lymphoma in RIT. Eur J Nucl Med Mol Imaging 2010;37(Suppl 2):S238
67. Malek E, Ferrer L, Bardiès M, Bodet-Millin C, Kraeber- Bodéré F, Huglo D et al. Dosimetry for fractionated Zevalin™ treatment as an initial therapy of follicular lymphoma. Eur J Nucl Med Mol Imaging 2010;37(Suppl 2):S237.
68. Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in Peptide radionuclide receptor therapy: a review. J Nucl Med 2006;47:1467-75. (Pubitemid 47544933)
69. Strigari L, Sciuto R, Rea S, Carpanese L, Pizzi G, Soriani A et al. Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations. J Nucl Med 2010;51:1377-85.
70. Hindorf C, Glatting G, Chiesa C, Lindén O, Flux G, and EANM Dosimetry Committee. EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging 2010;37:1238-50.
71. Sgouros G, Frey E, Wahl R, He B, Prideaux A, Hobbs R. Three-dimensional imaging-based radiobiological dosimetry. Semin Nucl Med 2008;38:321-34. (Pubitemid 352033565)
72. Wessels BW, Konijnenberg MW, Dale RG, Breitz HB, Cremonesi M, Meredith RF et al. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response-implications for radionuclide therapy. J Nucl Med 2008;49:1884-99